Cantor Fitzgerald reaffirmed their overweight rating on shares of Prenetics Global (NASDAQ:PRE - Free Report) in a research note published on Thursday morning,Benzinga reports. They currently have a $9.00 price target on the stock.
Prenetics Global Stock Down 1.2 %
Shares of PRE traded down $0.07 during midday trading on Thursday, reaching $5.93. The stock had a trading volume of 4,747 shares, compared to its average volume of 10,795. Prenetics Global has a 52 week low of $2.85 and a 52 week high of $7.84. The firm's 50 day moving average price is $5.16 and its 200-day moving average price is $5.08.
Prenetics Global Company Profile
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
Read More
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
